Morgan Stanley stock jumps after earnings beat as dealmaking fees surge
16 January 2026
2 mins read

Morgan Stanley stock jumps after earnings beat as dealmaking fees surge

New York, January 15, 2026, 18:14 (EST) — Post-market trading

  • Shares of MS jumped 5.8% after Thursday’s market close.
  • Q4 profit exceeded estimates, driven by a 47% surge in investment banking revenue.
  • Morgan Stanley announced a quarterly dividend of $1.00, set for payment on Feb. 13.

Morgan Stanley shares rose 5.8% to $191.23 after U.S. markets closed Thursday, following better-than-expected fourth-quarter profits driven by stronger dealmaking. Investment banking revenue surged 47% to $2.41 billion. CFO Sharon Yeshaya told Reuters she sees an “accelerating pipeline” in M&A and IPOs — mergers and acquisitions and initial public offerings. The stock has climbed about 41% in 2025, trailing Goldman Sachs but outpacing the S&P 500. (Reuters)

The print arrives at a sensitive time for bank stocks. Investors are weighing if last year’s surge in corporate dealmaking and IPOs will extend into 2026 or falter as markets jitter and boards turn cautious once more.

Goldman Sachs, a major competitor, posted a double-digit profit increase this quarter, with initial bank earnings maintaining sector momentum. The coming days will reveal if investors remain willing to pay a premium or begin questioning executives about the downturn ahead. (AP News)

Morgan Stanley’s Q4 results showed net revenue of $17.9 billion and net income of $4.4 billion, or $2.68 per share. Wealth management revenue climbed 13% to $8.43 billion, while total client assets in wealth and investment management hit $9.3 trillion. The bank bought back $1.5 billion in stock during the quarter and declared a $1.00 quarterly dividend payable on Feb. 13. It closed 2025 with a 15.0% common equity tier 1 ratio, a crucial capital measure. (SEC)

During the earnings call, CEO Ted Pick flagged the “complicated” macro backdrop but noted that capital markets are “kicking in.” Yeshaya highlighted that “investment banking pipelines remain healthy,” citing improved underwriting and advisory activity. Pick added he plans to remain patient on acquisitions and maintain a high bar. (The Motley Fool)

Debt underwriting and M&A advisory drove the bulk of the investment banking gains. Equities stayed steady, supported by client activity and financing flows. Fixed income lagged, especially in sectors linked to commodities and foreign exchange.

Wealth management has stepped up as the anchor, softening the blow during slow spells in trading and underwriting.

Despite that change, valuations remain high compared to historical norms. A Reuters Breakingviews column noted Morgan Stanley trades near 3.1 times expected book value—that’s the share price relative to net assets on the balance sheet—surpassing levels seen before the financial crisis. Goldman Sachs sits at about 2.7 times. (Reuters)

A deal revival could lose steam quickly if equity markets falter or doubts grow over how fast rate cuts will come. High asset prices boost the risk of dips in trading and advisory fees. Plus, credit losses might reappear in vulnerable areas, such as commercial real estate.

Traders will watch MS shares closely in the next session, seeking signs of momentum and clearer insight into whether the pipeline is turning into actual closed deals and listings as 2026 begins. The key date ahead is Jan. 30, the record date for the $1.00 dividend payable on Feb. 13.

Stock Market Today

  • Emera (EMA) valuation after five-year rally: DDM signals undervaluation
    January 15, 2026, 6:45 PM EST. Emera trades at CA$67.91, after a five-year run in which the stock rose about 64.7% and posted 33.2% gains over the last year. The group is viewed as a Canadian utilities proxy, with investors weighing valuation against peers using metrics such as P/E and dividend yield. Simply Wall St assigns Emera a 5/6 on its valuation checklist. On the Dividend Discount Model front, a current annual dividend per share of CA$2.98, ROE of 8.11%, and a 62.22% payout generate an intrinsic value of about CA$88.59, implying the stock trades about 23.3% below that estimate - hence undervalued. The P/E stands at 18.64x, near the peer average. For long-term investors, the case rests on stability, cash flows, and how Emera compares to utility peers.
UnitedHealth stock climbs as UnitedHealthcare rolls out fast-pay Medicare Advantage pilot for rural hospitals
Previous Story

UnitedHealth stock climbs as UnitedHealthcare rolls out fast-pay Medicare Advantage pilot for rural hospitals

Bank of America stock steadies after earnings whiplash as rate-cap risk hangs over banks
Next Story

Bank of America stock steadies after earnings whiplash as rate-cap risk hangs over banks

Go toTop